Coeptis Therapeutics, Inc. (COEP) Research

Coeptis Therapeutics, Inc. is a biopharmaceutical company dedicated to the advancement and market introduction of both generic and proprietary pharmaceutical products, as well as cell therapy platforms, specifically for individuals battling cancer. Their current portfolio includes CD38-GEAR-NK, a Vy-Gen drug formulated to combat CD38-positive cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Complementing this, they offer CD38-Diagnostic, an in vitro screening tool designed to pinpoint which cancer patients would most likely benefit from specific anti-CD38 monoclonal antibody therapies. Beyond their core oncology focus, Coeptis has forged alliances, notably with Statera BioPharma for the development and market launch of STAT-201, intended for Crohn's disease. They also hold joint development and ownership rights for CPT60621, a potential treatment for Parkinson's Disease, through a collaboration with Vici Health Sciences, LLC. Established in 2017, Coeptis Therapeutics, Inc. is headquartered in Wexford, Pennsylvania.

Open Coeptis Therapeutics, Inc. (COEP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.